• Health Catalyst Invests In healthfinch

    To kick off the third quarter, Health Catalyst has announced its second acquisition of 2020. On July 9, the company announced it acquired healthfinch, Inc. for roughly $40 million. healthfinch provides a workflow integration engine delivering insights and analytics into EMR workflows to automate physicians’ ability to close patient care gaps in... Read More »
  • Second Quarter Healthcare M&A Activity Drops

    The decline in second quarter healthcare M&A probably won’t surprise many of our readers. The second quarter was the first full quarter of healthcare M&A in the shadow of the COVID-19 pandemic, and deal making took a hit as a result, as shown in results from our DSO database. Compared with Q1:20, Q2:20 dropped 20%, with 322 transactions... Read More »
  • Sanofi Inks New Licensing Deal

    Just weeks following its agreement with Translate Bio (NASDAQ: TBIO) for COVID-19 vaccine development, Sanofi (NYSE: SNY) has a new agreement with Kymera Therapeutics Inc. Sanofi and Kymera are signing a multi-program collaboration to develop and commercialize first-in-class protein degrader therapies targeting IRAK4 in patients with... Read More »
  • Summit BHC Expands Into West Virginia

    Private equity-backed Summit BHC has announced a new acquisition in West Virginia. The behavioral health treatment company added Highland Hospital to its network for an undisclosed sum. Meridian Behavioral Health Systems, LLC is selling Highland Hospital, an inpatient psychiatric facility (131 beds) with 24 beds dedicated to psychiatric... Read More »
  • Health Care M&A Deals, July 10, 2020

    The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week based on... Read More »
CooperSurgical Adds to Its IVF Business

CooperSurgical Adds to Its IVF Business

CooperSurgical (NYSE: COO), a subsidiary of The Cooper Companies, Inc., has added another medical device maker focused on women’s health. This is CooperSurgical’s first acquisition in 2018, and it didn’t go far from its Trumbull, Connecticut offices to find The LifeGlobal Group in Guilford, Connecticut. LifeGlobal is a leading provider of in vitro fertilization (IVF) products and devices, with operating facilities in the United States, Canada, Europe, Hong Kong and distributors in some 90 countries worldwide. The acquisition is expected to strengthen CooperSurgical’s fertility media offering and thus improve its industry leading fertility business overall. The deal... Read More »
CVS, Aetna Lead a Potential Big-Deal Parade

CVS, Aetna Lead a Potential Big-Deal Parade

The fourth quarter, and the month of December in particular, are usually busy times for mergers and acquisitions, and often when big deals are announced. With one month to go in Q4:17, the pace may be picking up. Deal volume through December 1 stood at 231 transactions (-39% to last year’s 379), and $19.6 billion (-49% vs. $38.6 billion in Q4:16). But late on December 3, CVS Health (NYSE: CVS) and managed care giant Aetna (NYSE: AET) announced their $69 billion merger. More mega-deals are in the offing. Possibly. The CVS/Aetna deal was first reported in October by The Wall Street Journal, with talk of $200 to $205 per share for Aetna. The final price is $207 per share in cash and... Read More »
Teva Begins to Pare Its Portfolio

Teva Begins to Pare Its Portfolio

Last week, Teva Pharmaceutical Industries Ltd. (NYSE: TVA) divested more than $1.1 billion of assets in response to increasing financial pressure. Just this August, Credit Suisse lowered its rating on Teva’s stock from neutral to underperform, citing industry-wide pricing pressure for generic drugs. Credit Suisse’s announcement follows Teva’s acquisition of Allergan’s (NYSE: AGN) generic division, Anda Inc., just a year ago, for $500 million. Teva is looking to pay down more than $35 billion in debt–an amount that exceeds its market value. To do so, the Israeli drug maker has pursued divestiture opportunities for its global Women’s Health business, as well as its Oncology and... Read More »